fresenius medical care-pref
(FMCMF:OTC US)
fresenius medical care-pref (FMCMF) Snapshot
|
Open
$67.80
|
Previous Close
$67.80
|
|
|
Day High
$67.80
|
Day Low
$67.80
|
|
|
52 Week High
05/1/13 - $67.90
|
52 Week Low
06/8/12 - $52.85
|
|
|
Market Cap
--
|
Average Volume 10 Days
10.0
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
05/17/13
|
P/E TM
--
|
|
|
Dividend
$0.76
|
Dividend Yield
1.46%
|
Related News
fresenius medical care-pref (FMCMF) Related Businessweek News
No Related Businessweek News Foundfresenius medical care-pref (FMCMF) Details
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. The company owns and operates dialysis clinics providing dialysis treatment, and related laboratory and diagnostic services. As of December 31, 2012, it provided dialysis treatment to 257,916 patients in 3,160 clinics worldwide. The company’s laboratory services include blood, urine, and other bodily fluid testing services. It also offers hemodialysis (HD) machines; modular components for dialysis machines; polysulfone dialyzers; bloodlines, HD solutions, concentrates, and granulates; needles; connectors; machines for water treatment; data administration systems; dialysis chairs; phosphate binders; iron products; and other renal drug products, as well as peritoneal dialysis cycler machines and disposable products. In addition, the company also provides adsorbers, which are specialized filters used in other extracorporeal therapies; and distributes specific instruments for vascular access, as well as other supplies, such as bandages, clamps, and injections. Further, it offers dialysis solutions in bags, such as solutions for priming and rinsing HD bloodlines, as well as connection systems for central concentrate supplies and devices for mixing dialysis solutions; and solutions for disinfecting and decalcifying HD machines, fistula needles, and HD catheters, as well as dialysis tubing systems and accessories. Additionally, the company provides peritoneal dialysis systems and solutions comprising continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD). It also offers automated connection technology; and patient management software tools to support both CAPD and APD therapies. The company sells its products through local sales forces, independent distributors, dealers, and sales agents. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.
fresenius medical care-pref (FMCMF) Top Compensated Officers
fresenius medical care-pref (FMCMF) Key Developments
Fresenius Medical Care AG & Co. KGAA (DB:FME) is seeking acquisitions. Chief Executive Officer, Ulf Schneider, said, "We will strengthen our leading position in the German hospitals market with further acquisitions." This would be mainly as part of the ongoing privatization of state operated or church operated hospitals.
Fresenius Medical Care AG & Co. KGAA announced at the AGM held on May 16, 2013 that the shareholders approved the company's 16th consecutive dividend increase. The dividend will be raised to 0.75 from 0.69 per ordinary share, and to 0.77 from 0.71 per preference share.
Fresenius Medical Care AG & Co. KGAA reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, total net revenue was $3,463.921 million against $3,248.755 million a year ago. Operating income was $493.313 million against $502.966 million a year ago. Net income attributable to shareholders of FMC AG & Co. KGaA was $255.499 million or $0.74 per share against $370.498 million or $1.22 per share a year ago. EBITDA was $649.666 million against $646.340 million a year ago. Cash flow from operating activities was $315 million against $481 million a year ago. Free cash flow was $169 million against $359 million a year ago. For the full year 2013, the company confirmed its revenue and earnings outlook. The company expects revenue to grow to more than $14.6 billion in 2013, translating into a growth rate of more than 6%. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA is expected to be between $1.1 billion and $1.2 billion in 2013. For 2013, the company expects to spend around $700 million on capital expenditures and around $300 million on acquisitions. The debt/EBITDA ratio is expected to be equal or below 3.0 by the end of 2013.
| Recently Viewed | |||
| FMCMF:US | $67.80 USD | 0.00 |  |
| Company | Last | Change |
| Baxter International Inc | $71.65 USD | -0.65 |
| DaVita HealthCare Partners Inc | $125.22 USD | -0.89 |
| Shire PLC | 2,134 GBp | -21.00 |
| Terumo Corp | ¥5,250 JPY | -290.00 |
| Toray Industries Inc | ¥704.00 JPY | -65.00 |
| View Industry Companies | ||
Industry Analysis
FMCMF
Industry Average
| Valuation | FMCMF | Industry Range |
| Price/Earnings | 20.5x |
|
| Price/Sales | 1.5x |
|
| Price/Book | 2.3x |
|
| Price/Cash Flow | 20.2x |
|
| TEV/Sales | 0.8x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact FRESENIUS MEDICAL CARE-PREF, please visit www.fmc-ag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
